Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan

the J-CANSIS Research Group

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Medical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum. We evaluated changes in survival rates for this cancer following these advances by analyzing data from population-based cancer registries in Japan. Methods: Data were available for 8562 cases of cancer of the corpus uteri from six prefectural cancer registries. We defined the two periods of 1993-2000 (1st period) and 2001-2006 (2nd period). Relative survival (RS) in each period was calculated to assess changes using an excess mortality model, with adjustment for age group (15-54, 55-69, and 70-99 years), extent of disease (localized, regional, and distant), and histological subtype. Results: Overall 5-year RS improved from 77.7% in the 1st period to 80.2% in the 2nd period, with an excess hazard ratio (EHR) of 0.785 (95% confidence interval [CI], 0.705-0.873). Five-year RS significantly improved in the group aged 55-69 years, in all groups by extent of disease, and in the endometrioid adenocarcinoma group. In particular, 5-year RS significantly improved in patients with endometrioid adenocarcinoma, from 84.5% to 89.7%, with an EHR of 0.698 (95% CI, 0.560-0.870). Conclusion: Overall 5-year RS for cancer of the corpus uteri in Japan improved from the 1990s to early 2000s. These improvements might have been aided by the comprehensive medical development of management for this cancer, including the spread of concomitant therapy with taxane and platinum as a standard adjuvant chemotherapy in the early 2000s.

Original languageEnglish
Pages (from-to)75-80
Number of pages6
JournalJournal of epidemiology
Volume28
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Uterine Neoplasms
Japan
Survival
Endometrioid Carcinoma
Platinum
Registries
Neoplasms
Confidence Intervals
Adjuvant Chemotherapy
Survival Rate
Age Groups
Mortality
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Epidemiology

Cite this

Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan. / the J-CANSIS Research Group.

In: Journal of epidemiology, Vol. 28, No. 2, 01.01.2018, p. 75-80.

Research output: Contribution to journalArticle

@article{b5f0f2bece2142099079f6bfbd6c2ae0,
title = "Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan",
abstract = "Background: Medical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum. We evaluated changes in survival rates for this cancer following these advances by analyzing data from population-based cancer registries in Japan. Methods: Data were available for 8562 cases of cancer of the corpus uteri from six prefectural cancer registries. We defined the two periods of 1993-2000 (1st period) and 2001-2006 (2nd period). Relative survival (RS) in each period was calculated to assess changes using an excess mortality model, with adjustment for age group (15-54, 55-69, and 70-99 years), extent of disease (localized, regional, and distant), and histological subtype. Results: Overall 5-year RS improved from 77.7{\%} in the 1st period to 80.2{\%} in the 2nd period, with an excess hazard ratio (EHR) of 0.785 (95{\%} confidence interval [CI], 0.705-0.873). Five-year RS significantly improved in the group aged 55-69 years, in all groups by extent of disease, and in the endometrioid adenocarcinoma group. In particular, 5-year RS significantly improved in patients with endometrioid adenocarcinoma, from 84.5{\%} to 89.7{\%}, with an EHR of 0.698 (95{\%} CI, 0.560-0.870). Conclusion: Overall 5-year RS for cancer of the corpus uteri in Japan improved from the 1990s to early 2000s. These improvements might have been aided by the comprehensive medical development of management for this cancer, including the spread of concomitant therapy with taxane and platinum as a standard adjuvant chemotherapy in the early 2000s.",
author = "{the J-CANSIS Research Group} and Shusaku Inoue and Satoyo Hosono and Hidemi Ito and Isao Oze and Yoshikazu Nishino and Masakazu Hattori and Tomohiro Matsuda and Isao Miyashiro and Tomio Nakayama and Mika Mizuno and Keitaro Matsuo and Kiyoko Kato and Hideo Tanaka and Yuri Ito",
year = "2018",
month = "1",
day = "1",
doi = "10.2188/jea.JE20170008",
language = "English",
volume = "28",
pages = "75--80",
journal = "Journal of Epidemiology",
issn = "0917-5040",
publisher = "Japan Epidemiology Association",
number = "2",

}

TY - JOUR

T1 - Improvement in 5-year relative survival in cancer of the corpus uteri from 1993-2000 to 2001-2006 in Japan

AU - the J-CANSIS Research Group

AU - Inoue, Shusaku

AU - Hosono, Satoyo

AU - Ito, Hidemi

AU - Oze, Isao

AU - Nishino, Yoshikazu

AU - Hattori, Masakazu

AU - Matsuda, Tomohiro

AU - Miyashiro, Isao

AU - Nakayama, Tomio

AU - Mizuno, Mika

AU - Matsuo, Keitaro

AU - Kato, Kiyoko

AU - Tanaka, Hideo

AU - Ito, Yuri

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Medical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum. We evaluated changes in survival rates for this cancer following these advances by analyzing data from population-based cancer registries in Japan. Methods: Data were available for 8562 cases of cancer of the corpus uteri from six prefectural cancer registries. We defined the two periods of 1993-2000 (1st period) and 2001-2006 (2nd period). Relative survival (RS) in each period was calculated to assess changes using an excess mortality model, with adjustment for age group (15-54, 55-69, and 70-99 years), extent of disease (localized, regional, and distant), and histological subtype. Results: Overall 5-year RS improved from 77.7% in the 1st period to 80.2% in the 2nd period, with an excess hazard ratio (EHR) of 0.785 (95% confidence interval [CI], 0.705-0.873). Five-year RS significantly improved in the group aged 55-69 years, in all groups by extent of disease, and in the endometrioid adenocarcinoma group. In particular, 5-year RS significantly improved in patients with endometrioid adenocarcinoma, from 84.5% to 89.7%, with an EHR of 0.698 (95% CI, 0.560-0.870). Conclusion: Overall 5-year RS for cancer of the corpus uteri in Japan improved from the 1990s to early 2000s. These improvements might have been aided by the comprehensive medical development of management for this cancer, including the spread of concomitant therapy with taxane and platinum as a standard adjuvant chemotherapy in the early 2000s.

AB - Background: Medical circumstances in Japanese patients with cancer of the corpus uteri have greatly changed since the late 1990s, including the introduction of concomitant therapy with taxane and platinum. We evaluated changes in survival rates for this cancer following these advances by analyzing data from population-based cancer registries in Japan. Methods: Data were available for 8562 cases of cancer of the corpus uteri from six prefectural cancer registries. We defined the two periods of 1993-2000 (1st period) and 2001-2006 (2nd period). Relative survival (RS) in each period was calculated to assess changes using an excess mortality model, with adjustment for age group (15-54, 55-69, and 70-99 years), extent of disease (localized, regional, and distant), and histological subtype. Results: Overall 5-year RS improved from 77.7% in the 1st period to 80.2% in the 2nd period, with an excess hazard ratio (EHR) of 0.785 (95% confidence interval [CI], 0.705-0.873). Five-year RS significantly improved in the group aged 55-69 years, in all groups by extent of disease, and in the endometrioid adenocarcinoma group. In particular, 5-year RS significantly improved in patients with endometrioid adenocarcinoma, from 84.5% to 89.7%, with an EHR of 0.698 (95% CI, 0.560-0.870). Conclusion: Overall 5-year RS for cancer of the corpus uteri in Japan improved from the 1990s to early 2000s. These improvements might have been aided by the comprehensive medical development of management for this cancer, including the spread of concomitant therapy with taxane and platinum as a standard adjuvant chemotherapy in the early 2000s.

UR - http://www.scopus.com/inward/record.url?scp=85047922347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047922347&partnerID=8YFLogxK

U2 - 10.2188/jea.JE20170008

DO - 10.2188/jea.JE20170008

M3 - Article

VL - 28

SP - 75

EP - 80

JO - Journal of Epidemiology

JF - Journal of Epidemiology

SN - 0917-5040

IS - 2

ER -